Conditions: Thymoma Thymic Carcinoma
Keywords: Thymoma Thymic Carcinoma
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 27
Healthy volunteers: no

Brief summary:
To study the efficacy of Alimta as a single agent in thymic cancers

Detailed description:
The broad range of clinical activity of thymic carcinomas makes the likelihood of detecting efficacy of a single agent such as premetrexed a reasonable objective since these malignancies are relatively slow growing and exhibit a broad range of chemosensitivity to antineoplastic agents.

Arms:
arm 1: Pemetrexed infusion once every 21 days (one cycle).

Interventions: intervention 1: Premetrexed (Alimta)
Intervention descriptions: intervention 1: Pemetrexed will be 500 mg/m2 IV every 3 weeks

Protocol document: